Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis

BACKGROUND: The cardiovascular outcome trials (CVOTs) have shown that glucagon like peptide-1 receptor agonists (GLP1RAs) have varying degrees of cardiovascular (CV) safety in patients with type 2 diabetes mellitus (T2DM.) The lack of any head-to-head comparative trials among GLP1RAs urged the need...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfayez, Osamah M., Almohammed, Omar A., Alkhezi, Omar S., Almutairi, Abdulaali R., Al Yami, Majed S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310317/
https://www.ncbi.nlm.nih.gov/pubmed/32571416
http://dx.doi.org/10.1186/s12933-020-01070-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310317/
https://www.ncbi.nlm.nih.gov/pubmed/32571416
http://dx.doi.org/10.1186/s12933-020-01070-z

Ejemplares similares